Hospital
Dickinson County Healthcare System
Dickinson County Healthcare System was paid $10.23M by Medicaid between Jan 2018 and Dec 2024, across 231 billing codes. Its largest line is 99284, emergency room visit (serious) — 17% of everything it billed.
33Billing provider infoDICKINSON COUNTY HEALTHCARE SYSTEM
IRON MOUNTAIN, MI 49801
IRON MOUNTAIN, MI 49801
33aNPI1801887013assigned 11/04/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$10.23M
24GClaims430,184
24DCodes billed231
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Michigan
Rank by total paid#63 of 86
Median peer was paid$21.55M
This provider vs. median0.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official MUNSON, JOLYN controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 65,799 | $1.29M | |
| 2019 | 53,820 | $1.12M | |
| 2020 | 49,680 | $1.06M | |
| 2021 | 63,500 | $1.58M | |
| 2022 | 74,090 | $1.90M | |
| 2023 | 72,123 | $1.89M | |
| 2024incomplete | 51,172 | $1.39M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 17% | 11,534 | 10,145 | $1.74M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 15% | 6,613 | 5,904 | $1.49M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 10% | 9,821 | 9,113 | $1.04M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 7.0% | 13,943 | 10,682 | $714K |
| 96361 | Intravenous infusion, hydration; each additional hour | 4.5% | 8,244 | 6,070 | $460K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 4.0% | 5,464 | 2,966 | $414K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.9% | 5,938 | 5,152 | $394K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.3% | 2,802 | 2,562 | $334K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.8% | 12,582 | 3,500 | $283K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 2.3% | 3,037 | 2,831 | $239K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.7% | 2,778 | 1,950 | $177K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.4% | 1,981 | 1,797 | $145K |
219 more codes
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.4% | 715 | $138K |
| 59025 | Fetal non-stress test | 1.3% | 1,575 | $133K |
| 71046 | Radiologic examination, chest; 2 views | 1.2% | 4,364 | $126K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.2% | 6,015 | $121K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.1% | 2,564 | $112K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 4,561 | $100K |
| 80053 | Comprehensive metabolic panel | <1% | 26,131 | $90K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 295 | $90K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 5,782 | $87K |
| 80061 | Lipid panel | <1% | 5,508 | $78K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,124 | $71K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 27,735 | $67K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 3,530 | $66K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 8,322 | $61K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,807 | $58K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,806 | $58K |
| 71045 | Radiologic examination, chest; single view | <1% | 2,105 | $49K |
| 20610 | <1% | 388 | $45K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,093 | $44K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,572 | $44K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 810 | $43K |
| 97161 | <1% | 1,036 | $42K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 450 | $41K |
| 76830 | Ultrasound, transvaginal | <1% | 695 | $36K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 2,835 | $36K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 2,048 | $33K |
| 36415 | Collection of venous blood by venipuncture | <1% | 32,225 | $29K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 67 | $29K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 563 | $27K |
| 86850 | <1% | 1,801 | $24K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 1,125 | $24K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,760 | $22K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,507 | $22K |
| 87088 | <1% | 6,497 | $21K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,941 | $21K |
| 94060 | <1% | 210 | $21K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 226 | $21K |
| 80306 | <1% | 3,915 | $21K | |
| 88142 | <1% | 1,451 | $20K | |
| 80055 | <1% | 797 | $19K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 557 | $19K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 446 | $18K |
| 96367 | <1% | 330 | $18K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 780 | $17K |
| 73630 | <1% | 1,345 | $16K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 160 | $16K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 79 | $16K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,749 | $16K |
| 97597 | <1% | 329 | $15K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 6,962 | $15K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 139 | $15K |
| 81001 | <1% | 15,270 | $14K | |
| 72100 | <1% | 487 | $14K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,419 | $14K |
| 84439 | <1% | 2,889 | $13K | |
| 73610 | <1% | 891 | $12K | |
| 86703 | <1% | 1,515 | $12K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,012 | $11K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 135 | $10K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,308 | $10K |
| 82728 | <1% | 1,635 | $10K | |
| 84484 | <1% | 4,544 | $10K | |
| 87186 | <1% | 2,640 | $9K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 162 | $9K |
| 87081 | <1% | 2,464 | $9K | |
| 82607 | <1% | 1,228 | $8K | |
| 83880 | <1% | 974 | $8K | |
| 86618 | <1% | 1,096 | $8K | |
| 83735 | <1% | 5,347 | $8K | |
| 87077 | <1% | 2,252 | $8K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 5,047 | $8K |
| 83605 | <1% | 3,197 | $7K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 76 | $7K |
| 83690 | <1% | 4,270 | $7K | |
| 93976 | <1% | 137 | $7K | |
| 82803 | <1% | 1,513 | $7K | |
| 73562 | <1% | 517 | $6K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 543 | $6K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 554 | $6K |
| 73110 | <1% | 438 | $6K | |
| 73130 | <1% | 544 | $6K | |
| 81025 | <1% | 3,109 | $6K | |
| 73030 | <1% | 536 | $6K | |
| 84703 | <1% | 2,046 | $5K | |
| 86140 | <1% | 3,588 | $5K | |
| 87400 | <1% | 582 | $5K | |
| 84702 | <1% | 811 | $5K | |
| 85027 | <1% | 2,279 | $5K | |
| 87653 | <1% | 326 | $5K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 141 | $5K |
| 74019 | <1% | 574 | $5K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 15 | $4K |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 18 | $4K |
| 71271 | <1% | 80 | $4K | |
| 87070 | <1% | 1,207 | $4K | |
| 85610 | <1% | 3,005 | $4K | |
| 82570 | <1% | 1,333 | $4K | |
| 87040 | <1% | 1,678 | $4K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 30 | $4K |
| 87205 | <1% | 1,911 | $4K | |
| 87147 | <1% | 1,550 | $3K | |
| 84481 | <1% | 332 | $3K | |
| 88342 | <1% | 329 | $3K | |
| 93971 | <1% | 60 | $3K | |
| 85730 | <1% | 1,838 | $2K | |
| 85651 | <1% | 1,524 | $2K | |
| 76775 | <1% | 75 | $2K | |
| 86803 | <1% | 267 | $2K | |
| 83540 | <1% | 723 | $2K | |
| 97113 | <1% | 35 | $2K | |
| 82950 | <1% | 731 | $2K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 152 | $2K |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 12 | $2K |
| 97162 | <1% | 49 | $2K | |
| 85007 | <1% | 1,847 | $2K | |
| 83550 | <1% | 452 | $2K | |
| 85379 | <1% | 857 | $2K | |
| 87420 | <1% | 293 | $2K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 141 | $2K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 26 | $2K |
| 95886 | <1% | 167 | $1K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 249 | $1K |
| 74018 | <1% | 113 | $1K | |
| 84156 | <1% | 673 | $1K | |
| 94664 | <1% | 247 | $1K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 78 | $1K |
| 86900 | <1% | 111 | $999.78 | |
| 87210 | <1% | 369 | $973.16 | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 109 | $911.59 |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 158 | $824.83 |
| 82746 | <1% | 130 | $796.66 | |
| 85652 | <1% | 805 | $787.55 | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 20 | $766.34 |
| 86677 | <1% | 247 | $704.21 | |
| 73502 | <1% | 89 | $698.16 | |
| 87468 | <1% | 44 | $621.91 | |
| 87469 | <1% | 44 | $617.58 | |
| 87484 | <1% | 44 | $615.41 | |
| G0378 | Hospital observation service, per hour | <1% | 238 | $588.62 |
| 93017 | <1% | 18 | $534.60 | |
| 82043 | <1% | 140 | $532.72 | |
| 84550 | <1% | 309 | $504.63 | |
| 87501 | <1% | 27 | $454.18 | |
| 87340 | <1% | 78 | $394.97 | |
| 82150 | <1% | 172 | $366.10 | |
| 11721 | <1% | 28 | $334.18 | |
| 87478 | <1% | 28 | $324.99 | |
| 82550 | <1% | 128 | $296.15 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 5,152 | $280.83 |
| 82784 | <1% | 26 | $275.61 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 46 | $274.38 |
| 76377 | <1% | 4,292 | $226.69 | |
| 84153 | <1% | 13 | $212.96 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 12 | $146.12 |
| 86706 | <1% | 25 | $138.60 | |
| 86901 | <1% | 227 | $132.86 | |
| 80076 | <1% | 27 | $124.61 | |
| 86038 | <1% | 13 | $114.22 | |
| 84145 | <1% | 29 | $112.52 | |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | <1% | 145 | $103.55 |
| 86704 | <1% | 13 | $79.65 | |
| J2704 | Injection, propofol, 10 mg | <1% | 2,411 | $74.33 |
| 84100 | <1% | 41 | $70.66 | |
| 86708 | <1% | 12 | $69.10 | |
| 84436 | <1% | 25 | $65.58 | |
| 36591 | <1% | 28 | $64.79 | |
| 84450 | <1% | 15 | $60.14 | |
| 74022 | <1% | 53 | $58.26 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 807 | $58.10 |
| 86592 | <1% | 19 | $46.53 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,811 | $46.11 |
| 94726 | <1% | 26 | $40.96 | |
| 81003 | <1% | 500 | $39.80 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,840 | $28.30 |
| 88304 | <1% | 41 | $27.98 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,658 | $27.20 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,047 | $26.48 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,259 | $22.50 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,926 | $21.40 |
| 94729 | <1% | 26 | $20.48 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,786 | $18.58 |
| 94727 | <1% | 25 | $15.36 | |
| 96376 | <1% | 974 | $10.50 | |
| 82962 | <1% | 15 | $10.05 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 6,170 | $7.80 |
| 99153 | Mod sedat endo service >5yrs | <1% | 204 | $3.71 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,624 | $3.31 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 614 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 1,777 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 232 | $0.00 |
| J3490 | Unclassified drugs | 0% | 1,179 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 1,390 | $0.00 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 125 | $0.00 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 41 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 230 | $0.00 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 249 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 521 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 51 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 75 | $0.00 |
| 99156 | 0% | 13 | $0.00 | |
| 94760 | 0% | 24 | $0.00 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 12 | $0.00 |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | 0% | 286 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 909 | $0.00 |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 0% | 1,184 | $0.00 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 483 | $0.00 |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | 0% | 394 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 44 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 325 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 21 | $0.00 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 0% | 102 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 180 | $0.00 |
| 99152 | 0% | 94 | $0.00 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 70 | $0.00 |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | 0% | 30 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 16 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 28 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 12 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMUNSON, JOLYN (VP REVENUE CYCLE OPERATIONS)
Parent organizationMARSHFIELD CLINIC HEALTH SYSTEM INC
| Provider | Location | Paid |
|---|---|---|
| MCHS Hospitals INC | Marshfield, WI | $45.31M |
| Marshfield Clinic INC | Marshfield, WI | $19.61M |
| MCHS Hospitals INC | Eau Claire, WI | $12.41M |
| MCHS Hospitals INC | Marshfield, WI | $11.82M |
| Beaver Dam Community Hospitals INC | Beaver Dam, WI | $10.58M |
| MCHS Hospitals INC | Ladysmith, WI | $7.36M |
| MCHS Hospitals INC | Weston, WI | $6.40M |
| MCHS Hospitals INC | Eau Claire, WI | $4.14M |
| MCHS Hospitals INC | Minocqua, WI | $2.90M |
| Dickinson County Healthcare System | Iron Mountain, MI | $2.44M |
| Dickinson County Healthcare System | Iron Mountain, MI | $2.29M |
| MCHS Hospitals INC | Wausau, WI | $1.84M |
| MCHS Hospitals INC | Weston, WI | $1.22M |
| MCHS Hospitals INC | Minocqua, WI | $1.16M |
| MCHS Hospitals INC | Marshfield, WI | $988K |
| MCHS Hospitals INC | Ladysmith, WI | $867K |
| Beaver Dam Community Hospitals INC | Beaver Dam, WI | $847K |
| Dickinson County Healthcare System | Iron Mountain, MI | $648K |
| MCHS Hospitals INC | Marshfield, WI | $563K |
| MCHS Hospitals INC | Minocqua, WI | $338K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.